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Anti-drug antibody detection with label-free
electrolyte-gated organic field-effect transistors†
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Andrea Conti, b Giovanni Pellacani,b Carlo Salvarani,c Andrea Cossarizza,d
Carlo Augusto Bortolotti a and Fabio Biscarini *ae
The efficacy of immunotherapy can be undermined by the develop-
ment of an immune response against a drug/antibody mediated by
anti-drug antibodies (ADAs) in treated patients. We present the first
label-free EGOFET immunosensor that integrates a biological drug,
Nivolumab (Opdivor), as a specific recognition moiety to quantita-
tively and selectively detect ADAs against the drug. The limit of
detection is 100 fM. This demonstration is a prelude to the detection
of ADAs in a clinical setting in the treatment of different pathologies,
and it also enables rapid screening of biological drugs for
immunogenicity.
The recent development of biotechnological drugs is greatly
improving the pharmacological treatment of many diseases. An
example of this therapeutic innovation is immunotherapy,
which has been proven effective against some types of cancer
(melanoma, lung, colon, liver, kidney, and head)1–3 and inflam-
matory chronic diseases (psoriasis, rheumatoid arthritis,
Crohn’s disease, and systemic lupus erythematosus).4–6
In tumors, cancer cells can evade the immune surveillance
thanks to different resistance mechanisms, including the sti-
mulation of immune checkpoints. Immune checkpoints are
essential for self-tolerance, which prevents the indiscriminate
action of the immune system towards any cell in an organism
and is central in autoimmune diseases. It has been demon-
strated that inhibiting immune checkpoints induces a large
T cell response against cancer cells.7 In 2011, the FDA8 approved
the first clinically validated checkpoint inhibitor called Ipilinu-
mab, a monoclonal antibody that blocks the receptor Cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4), an immune check-
point that downregulates the immune response. Another
approved checkpoint inhibitor is Nivolumab (Opdivor),9
which shows promising results in the treatment of melanoma,
Hodgkin’s lymphoma, non-small cell lung cancer,1,10–12 renal
cell carcinoma, liver cancer, bladder cancer, head and neck
cancer and colon cancer. Nivolumab is a fully human IgG4
monoclonal antibody which blocks the Programmed cell-death
protein 1 (PD-1), an inhibitory transmembrane protein
expressed by T cells. Binding of PD-1 to its cognate ligands
PD-L1/2,13 highly expressed by cancer cells, triggers several
mechanisms that dampen the immune response, such as
exhaustion of peripheral T effector cells and conversion of
effector T cells to regulatory T cells.14,15 Thus, blockade of the
PD-1 pathway by Nivolumab enhances the T cell anti-tumor
activity and thereby favours killing of cancer cells.16,17 Unfortu-
nately, a side effect of Nivolumab and other checkpoint inhi-
bitors is the development of an immune response against the
drug itself, mediated by anti-drug antibodies (ADAs).18–20 ADAs
are found in 12.7% of patients under Nivolumab therapy19 and
their detection is not trivial mainly due to the absence of a
homogeneous ADA population and concentration (ranging
from few ng ml1 to almost 1 mg ml1) and the technical
difficulty of detecting ADAs once in complex with the drug.
The main strategies currently used to detect ADAs are ELISA,
homogeneous mobility shift assay (HMSA), electrochemilumi-
nescence (ECL) immunoassay, and cell-based reporter-gene
assay (RGA).18,21 All these methods allow the detection of ADAs
with a minimum LOD between 10 pM and 100 pM, but they
require labels (fluorescent dyes and enzymes), specialized
laboratories and/or qualified personnel. The development of a
fast biosensor to detect ADAs in the patient plasma with a point
of care (POC) approach could facilitate the early detection of
adverse immune responses. In the field of POC biosensors,
organic electronics is an attractive platform because it enables
the fabrication of devices that are ultrasensitive and biocompatible,
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and that can be made flexible and impalpable, and fabricated
in a low cost, high throughput method. Electrolyte-gated
organic field-effect transistors (EGOFETs) are among the most
widely explored device architectures for biosensing with
organic electronics.22–24 EGOFETs are three-electrode devices
operated in a capacitive coupling. An organic semiconductor
channel transduces a small voltage bias into a large signal in
the presence of an electrolyte. Functionalization of a gate
electrode with a recognition moiety, such as an antibody, an
aptamer, an enzyme, or a whole virus or bacterium, can make
its response selective towards a given target, a necessary
requisite for its operation as a biosensor. Thanks to their ability
to amplify small signals and the low limit of detection, EGO-
FETs were shown to be state-of-the-art sensors for the detection
of organic chemicals,25 metals,26 water pollutants,27 proteins,23,28,29
nucleic acids30 and viruses.31
In this work, we show the first EGOFET immunosensor able
to detect ADAs; in particular, we validate the biosensor for the
detection of commercial anti-Nivolumab antibodies. The device
embodies an Au gate functionalized to immobilize Nivolumab
as an ADA specific probe. By measuring the electrical charac-
teristics of the device exposed to ADAs in buffer, we obtain a
dose curve enabling anti-Nivolumab ADAs across four orders
of magnitude with a theoretical limit of detection as low as
100 fM. This work indicates a possibility to dose ADAs with a
sensing platform that is portable and easy to upscale, can be
tailored to clinicians’ needs, and can be used at the POC
without any particular training of the personnel.
EGOFETs were patterned on a quartz substrate, featuring
two interdigitated (width-to-length ratio W/L = 500) gold elec-
trodes as the source and the drain. The semiconductor channel
was made of TIPS-pentacene thin films by spin-coating. To
perform specific biosensing, we functionalized the gate elec-
trode with the drug Nivolumab as the probe. As a first step, we
chemisorbed Cys-protein G on the gold surface of the gate by
means of the thiol group of an engineered exposed cysteine that
binds to the Au electrode. Since protein G binds specifically to
the Fc region of antibodies, the binding geometry of Nivolumab
results in exposure to the solution of the Fab region, which
is the docking site of ADAs. In the second step, the free gold
surface was saturated with an OEG (11-mercaptoundecyl-
triethylene glycol) self-assembled monolayer (SAM) (see Fig. 1),
with the aim to minimize nonspecific binding of Nivolumab and
ADAs on the surface of the gate electrode. This step is necessary
to minimize, if not deplete completely, the non-specific binding
of the ADAs on gold (see Fig. S2, ESI†). Cyclic voltammetry and
electrochemical impedance spectroscopy measurements in the
presence of the redox probe K3[Fe(CN)6] were used to assess the
functionalization strategy by monitoring the increased resis-
tance to charge transfer following each functionalization
step. As shown in Fig. 2a, chemisorption of protein G decreases
the redox peak intensity, and the partial surface coverage
(B40%) can be inferred. Since the formation of the OEG
monolayer leads to almost full passivation of the electrode,
binding of Nivolumab to protein G only induces minor further
changes.
The biosensing activity was tested by incubating the func-
tionalized gate in solutions of ADAs at different concentrations,
from 1 pM to 10 nM, for 20 minutes each. This time is normally
enough for validating the device and the procedure does not
affect its performance (Fig. S5, ESI†). We used anti-Nivolumab
ADAs that are recombinant, inhibitory anti-idiotypic monoclo-
nal antibodies in the monovalent Fab format (B50 kDa). This
form was chosen to avoid their binding to proteins G and
so test the specificity of the probe. By recording the transfer
characteristics after each incubation, we observed a decrease
in the drain–source current (IDS) and a shift of the threshold
voltage (VTH) (Fig. 3, panel a). The response of the biosensor
is expressed as S = DI/I0, where I0 is the IDS current measured
at [ADA] = 0, whileDI is the difference between IDS at a specific
ADA concentration and I0, and the gate bias is VGS = 0.2 V
and VDS = 0.2 V (linear regime). The response reveals a
Hill-type behaviour, with saturation at higher concentrations




1þ KaH ADA½ 
a (1)
we obtained a binding association constant KH value of (5.1 0.9)
1011 M1, with a cooperativity exponent a = 0.64  0.07.
By fitting the Langmuir equation to the data (Fig. 3b):
S ¼ Smax
KL ADA½ 
1þ KL ADA½ 
(2)
we obtained a binding association constant KL of (4.5  1.0) 
1011 M1, comparable to the value obtained by fitting the data
with the Hill-type model.
The available commercial ELISA kit (for research purpose
only) helps in qualitative (Abcam, Biovision, ELISA Genie) or
semi-quantitative (IBL-America, sensitivity B 67 pM) detection
of anti-Nivolumab ADAs in the serum or plasma. Our device
Fig. 1 EGOFET and the gate functionalization scheme. The EGOFET was
fabricated on a quartz substrate, with interdigitated drain and source gold
electrodes. A TIPS-pentacene OSC thin film covers the channel (optical
microscopy picture in the inset). A PBS drop connects the channel and the
top-gate electrode. The gate, as shown in the top inset, is functionalized
with protein G and OEG monolayers, the Fc region of Nivolumab binds




































































































This journal is©The Royal Society of Chemistry 2021 Chem. Commun., 2021, 57, 367--370 | 369
can detect ADAs in PBS in pM range concentrations, with a
limit of detection (LOD) = 100 fM, which is well within the
physiopathological range.
We determined the sensitivity of the device as a numerical
derivative dS/d[ADA] (see Fig. S3, ESI†). The sensitivity is higher at
lower concentrations of ADA (1  1011 M1 at 1 pM ADA), while it
decreases by 4 orders of magnitude in the nanomolar range.
By applying a linear fit on the transfer curves, we extracted
the transconductance (gm) from the slope and the threshold
voltage (VTH) from the intercept between the baseline current
(off-current) and the transfer curve, upon incubation of the gate
with each ADA solution (Fig. S8a, ESI†). The transconductance
as a function of ADA concentration presents a small decrease
(0.05 mS) at first exposure to ADAs (1 pM) and then saturates
to a plateau. On the contrary, the threshold voltage shifts at
larger absolute values, following a power law trend as a func-
tion of ADA concentration. This behaviour of the transistor
parameters was confirmed independently by extracting them
from the maximum of the first derivative (for gm) and the
minimum of the second derivative (for VTH) of the transfer
curve (see Fig. S4, ESI†).
The absence of effects on the transconductance of the device
and the negative shift of the threshold voltage from about 0 V to
0.25 V over four decades of ADA concentration, both suggest
that the binding of ADAs to the drug immobilized on the gate
shifts its electrochemical potential downward, leading to lesser
mobile holes in the p-type semiconductor.29 This may be
rationalized by assuming that a negative charge results from
the ADA/Nivolumab adduct, thus perturbing the potential
within the electrical double layer at the interface with the gate
electrode, e.g. screening or enhancing the field created by the
gate potential. The result is that an opposite change (in this
case positive) is generated in the electrical double layer at the
interface between the organic semiconductor and the electro-
lyte. This effectively corresponds to the increase of the Fermi
level in the OSC. From a microscopic point of view, the extra
positive charge will increase the energy of the polaron levels
(p-type) and/or lower the energy of the neutral states, thus
enlarging the hopping barrier. The outcome is that the
current will exponentially decrease, which indeed agrees with
the experimental observation.
Hence, the VTH shift appears to be a suitable parameter for
monitoring the ADA concentration, as it scales linearly with the
signal, and exhibits no saturation in the nM range of the ADA
concentration. Fig. S8b (ESI†) shows a comparison of the VTH
extracted either from the linear fit of IDS (squares) or IDS
1/2
(circles). Both exhibit a linear correlation with the signal S with
a similar slope (sensitivity) for the same gate voltage used. By
changing the method to extract the VTH, we observe a shift of
200 mV, while the sensitivity and the signal trend are con-
served. The steeper lines, exhibiting higher sensitivity, are the
ones corresponding to the sub-threshold regime (VGS = 0.1 V).
To determine the selectivity of the Nivolumab–ADA binding,
we tested the response of the device to another anti-drug
antibody, anti-infliximab, also featuring the Fc fragment. As
shown in Fig. 4a, incubation of the gate in anti-infliximab ADA
(ATIs, black) solutions leads to a current decrease that is much
lower, hence clearly distinguishable, than the signal due to the
recognition of specific anti-Nivolumab ADAs (red). The mostly
linear signal observed for anti-infliximab ADAs is probably
related to non-specific interactions with Nivolumab, protein G
or the electrode surface. The absence of specific interaction
Fig. 3 Transfer characteristics and response of the device to ADA.
(a) Transfer curves of the device after incubation at different concentrations
of anti-Nivolumab ADAs, at VDS = 0.2 V. (b) Semilog plot of the signal S vs.
[ADAs] molar concentration at VGS = 0.2 V. The dashed curve denotes the
best fit with the Hill equation. Each data point represents the average of
4 different devices, at each concentration (only exceptions are 1 pM, 10 pM
and 100 pM with 8 devices), while the error bars are the standard deviation.
Fig. 4 Selectivity of detection. Comparison between the response of the
device towards anti-Nivolumab (red) and anti-infliximab (black) ADAs
based on (a) the signal calculated from the transfer curves (see Fig. S6a,
ESI†), in the semilog plot at VGS = 0.1 V and VDS = 0.2 V and (b) faradaic
electrochemical impedance spectroscopy. The error bars denote the
standard deviation on the average of three devices. In both panels the
Au electrodes were functionalized following the procedure shown in
Fig. S1 (ESI†).
Fig. 2 Monitoring of functionalization steps by electrochemical methods.
(a) Cyclic voltammetry and (b) electrochemical impedance spectroscopy
of the bare gate electrode (black) and after successive functionalization
by incubation with protein G (2 h, 2.5 mg ml1, red curve), OEG (20 min,
100 mM, blue) and Nivolumab (2 h, 1 mg ml1, magenta). The dashed lines
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between ATIs and the device was confirmed by electrochemical
impedance spectroscopy (Fig. 4b), by exposing the gate functio-
nalized with protein G, Nivolumab and OEG to 10 nM anti-
infliximab antibodies for 20 minutes. After recording the EIS
spectrum, the same gate was exposed for 20 min to 10 nM anti-
Nivolumab antibodies. The binding of anti-infliximab to the
Nivolumab-functionalized gate has a small effect on the charge
transfer resistance, the imaginary component of impedance is
not affected (Zim in Fig. S6b, ESI†), while the real component
impedance (Zre in Fig. S6b, ESI†) decreases at 1 Hz by 10 kO.
The binding of anti-Nivolumab to the Nivolumab-functionalized
gate increases both the imaginary component of impedance at
1 Hz by 20 kO and the real component impedance by 10 kO,
supporting the evidence of the decrease of capacitance and
the increase of charge transfer resistance. We also observed a
negligible signal by performing a sensing experiment, as a
control, with a device where the gate was functionalized
with infliximab and exposed to anti-Nivolumab ADAs (see
Fig. S7, ESI†).
In summary, this work shows that it is possible to dose ADAs
for a specific biological drug/antibody with high accuracy (LOD
= 100 fM), sensitivity (1 1011 M1 at 1 pM ADA) and selectivity.
This outstanding sensing performance is enabled by the char-
acteristic properties of organic semiconductors; in particular,
the tail of the density of states (DOS) of the semiconductor
imparts exponential amplification to minute changes of the
potential at the interface between the semiconductor and the
electrolyte.28 These potential changes originate in the electro-
lyte gated organic transistor by the displacement of ions at the
interface between the organic semiconductor and the electro-
lyte, in response to the changes of the electrochemical potential
at the gate electrode caused by biorecognition events. The
ultrasensitivity and ease of operation make the organic sensors
particularly apt for the POC testing or for the in-field deployed
application, a scenario that is very common nowadays. The
capability of detecting antibodies against a biological drug
makes the technology attractive for planning, monitoring,
and re-directing therapeutic plans based on biological drugs.
It can also serve for experimental screening of candidate
biological drugs with an in vitro assay that allows ranking them
by their immunogenicity. The impact of such sensing technology
is in principle enormous, as it can find applications in urgent
scenarios such as the COVID-SARS2 virus infection (COVID-19
disease). The next steps will be clinical validation with patients’
samples and benchmarking against state-of-the-art assays for
ADA quantification.
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2016, 100, 88–98.
14 L. M. Francisco, V. H. Salinas, K. E. Brown, V. K. Vanguri,
G. J. Freeman, V. K. Kuchroo and A. H. Sharpe, J. Exp. Med., 2009,
206, 3015–3029.
15 S. Amarnath, C. W. Mangus, J. C. M. Wang, F. Wei, A. He, V. Kapoor,
J. E. Foley, P. R. Massey, T. C. Felizardo, J. L. Riley, B. L. Levine,
C. H. June, J. A. Medin and D. H. Fowler, Sci. Transl. Med., 2011, 3, 1–14.
16 L. Guo, H. Zhang and B. Chen, J. Cancer, 2017, 8, 410–416.
17 M. A. Postow, M. K. Callahan and J. D. Wolchok, J. Clin. Oncol., 2015,
33, 1974–1982.
18 E. M. J. van Brummelen, W. Ros, G. Wolbink, J. H. Beijnen and
J. H. M. Schellens, Oncologist, 2016, 21, 1260–1268.
19 S. Agrawal, P. Statkevich, G. Bajaj, Y. Feng, S. Saeger, D. D. Desai,
J. S. Park, I. M. Waxman, A. Roy and M. Gupta, J. Clin. Pharmacol.,
2017, 57, 394–400.
20 M. Tocut, R. Brenner and G. Zandman-Goddard, Autoimmun. Rev.,
2018, 17, 610–616.
21 B. Gorovits, D. J. Baltrukonis, I. Bhattacharya, M. A. Birchler,
D. Finco, D. Sikkema, M. S. Vincent, S. Lula, L. Marshall and
T. P. Hickling, Clin. Exp. Immunol., 2018, 192, 348–365.
22 M. Berto, C. Diacci, R. D’Agata, M. Pinti, E. Bianchini, M. Di Lauro,
S. Casalini, A. Cossarizza, M. Berggren, D. Simon, G. Spoto,
F. Biscarini and C. A. Bortolotti, Adv. Biosyst., 2017, 1700072.
23 S. K. Sailapu, E. Macchia, I. Merino-Jimenez, J. P. Esquivel,
L. Sarcina, G. Scamarcio, S. D. Minteer, L. Torsi and N. Sabaté,
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24 D. Wang, V. Noël and B. Piro, Electronics, 2016, 5, 9.
25 S. Casalini, F. Leonardi, T. Cramer and F. Biscarini, Org. Electron.
physics, Mater. Appl., 2013, 14, 156–163.
26 T. T. K. Nguyen, H. V. Tran, T. T. Vu, S. Reisberg, V. Noël, G. Mattana,
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